(2S)-butyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate | 946511-84-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-butyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate
• 英文别名: 1-naphthyl(butoxy-L-alaninyl)phosphorochloridate；N-butyl N-[chloro(1-naphthyloxy)phosphoryl]-1-alaninate；n-Butyl N-[chloro(1-naphthyloxy)phosphoryl]-L-alaninate；naphthalen-1-yl (butoxy-L-alaninyl)phosphorochloridate；butyl (2S)-2-[[chloro(naphthalen-1-yloxy)phosphoryl]amino]propanoate
• CAS: 946511-84-8
• 化学式: C₁₇H₂₁ClNO₄P
• 分子量: 369.785
• InChiKey: ZCYDLWZWSYHRGF-LNHXHEARSA-N

物化性质

• 沸点：
  479.0±47.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-butyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate 、 5-氟-2'-脱氧脲核苷 在 N-甲基咪唑 作用下， 以 四氢呋喃 为溶剂， 以1%的产率得到5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl(butoxy-L-alaninyl)]phosphate
  参考文献：
  名称：

  Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside

  摘要：

  The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors. We herein report their phosphate prodrugs, ProTides, as promising new derivatives, which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation. They are also resistant to metabolic deactivation by phosphorolytic enzymes. We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid. regions. Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells. We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR. Data suggest these compounds to be worthy of further progression.

  DOI：

  10.1021/jm200815w
• 作为产物：
  描述：

  1-萘基二氯磷酸酯 、 (S)-alanine n-butyl ester hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2S)-butyl 2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate
  参考文献：
  名称：

  Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection

  摘要：

  本发明提供了结构式（I）的核苷酸芳基磷酰胺酯，这些化合物是RNA依赖性RNA病毒聚合酶抑制剂的前体。这些化合物是RNA依赖性RNA病毒复制抑制剂的前体，对于治疗RNA依赖性RNA病毒感染非常有用。它们特别适用作为乙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体，和/或用于治疗乙型肝炎感染。本发明还描述了含有这种核苷酸芳基磷酰胺酯的药物组合物，单独或与其他针对RNA依赖性RNA病毒感染，特别是HCV感染的药剂结合使用。还公开了使用本发明的核苷酸芳基磷酰胺酯来抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。

  公开号：

  US20100234316A1

文献信息

• 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140161770A1

  公开（公告）日：2014-06-12

  The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-氰基取代核苷衍生物及其药学上可接受的盐，其中B、X、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-氰基取代核苷衍生物的组合物，以及使用这些2'-氰基取代核苷衍生物治疗或预防患者HCV感染的方法。
• Phosphoramidate Derivatives of Nucleosides
  申请人：Centocor Ortho Biotech Products L.P.

  公开号：EP2166016A1

  公开（公告）日：2010-03-24

  Compounds of formula I : R1 is hydrogen, C1-C4alkyl, OH, C1-C4alkoxy; R2 is phenyl, optionally substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6alkyl, and C1-C6alkoxy, or R2 is naphtalenyl; R3 is hydrogen, C1-C6alkyl, benzyl; R4 is hydrogen, C1-C6alkyl, benzyl; or R3 and R4 together with the carbon atom to which they are attached form C3-C7cycloalkyl; R5 is C1-C6alkyl, benzyl, or phenyl, optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, C1-C6alkoxy, amino, mono- and diC1-C6alkylamino; or a pharmaceutically acceptable salt or solvate thereof; useful in the prophylaxis or treatment of HCV infections.

  公式I的化合物：R1是氢、C1-C4烷基、羟基、C1-C4烷氧基；R2是苯基，可选地取代有1、2或3个取代基，每个取代基独立选择自卤素、C1-C6烷基和C1-C6烷氧基，或者R2是萘基；R3是氢、C1-C6烷基、苄基；R4是氢、C1-C6烷基、苄基；或者R3和R4与它们连接的碳原子一起形成C3-C7环烷基；R5是C1-C6烷基、苄基或苯基，可选地取代有1、2或3个取代基，每个取代基独立选择自羟基、C1-C6烷氧基、氨基、单烷基和双烷基氨基；或其药学上可接受的盐或溶剂；用于预防或治疗丙型肝炎感染。
• [EN] 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] ANALOGUES DE NUCLÉOSIDES 5'-SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013009737A1

  公开（公告）日：2013-01-17

  The present invention relates to 5'-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3' are as defined herein. The present invention also relates to compositions comprising at least one 5'-Substituted Nucleoside Analog, and methods of using the 5'-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的5'-取代核苷类似物及其药用盐，其中B、X、Z、R1、R2、R3和R3'如本文所定义。本发明还涉及包含至少一种5'-取代核苷类似物的组合物，以及使用这些5'-取代核苷类似物治疗或预防患者HCV感染的方法。
• [EN] SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS<br/>[FR] NUCLÉOSIDES DE PURINE SUBSTITUÉS, DÉRIVÉS PHOSPHORAMIDATE ET PHOSPHORDIAMIDATE DESTINÉS À TRAITER DES INFECTIONS VIRALES
  申请人：INHIBITEX INC

  公开号：WO2013070887A1

  公开（公告）日：2013-05-16

  This invention is directed to compounds of Formula (I) having the structure that are useful in the treatment of viral infections in mammals, particularly in humans, mediated, at least in part, by a virus in the Flaviviridae family of viruses.

  这项发明涉及具有结构的化合物（I）的公式，这些化合物在哺乳动物，特别是人类中，用于治疗由黄病毒科病毒介导的病毒感染。
• [EN] 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES 5'-SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013009735A1

  公开（公告）日：2013-01-17

  The present invention relates to 5'-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, Z, R1, R2, R3 and R3' are as defined herein. The present invention also relates to compositions comprising at least one 5'-Substituted Nucleoside Derivative, and methods of using the 5'-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的5'-取代核苷衍生物及其药学上可接受的盐，其中B、X、Y、Z、R1、R2、R3和R3'如本文所定义。本发明还涉及包含至少一种5'-取代核苷衍生物的组合物，以及使用这些5'-取代核苷衍生物治疗或预防患者HCV感染的方法。